Hennion & Walsh Asset Management, Inc. Tg Therapeutics, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.15 Billion
- Q1 2025
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 95,171 shares of TGTX stock, worth $3.4 Million. This represents 0.18% of its overall portfolio holdings.
Number of Shares
95,171
Previous 97,633
2.52%
Holding current value
$3.4 Million
Previous $2.94 Million
29.1%
% of portfolio
0.18%
Previous 0.14%
Shares
17 transactions
Others Institutions Holding TGTX
# of Institutions
416Shares Held
88.1MCall Options Held
2.34MPut Options Held
1.94M-
Vanguard Group Inc Valley Forge, PA15.6MShares$558 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$407 Million0.0% of portfolio
-
State Street Corp Boston, MA7.43MShares$266 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.28MShares$117 Million0.01% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.85MShares$102 Million9.29% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $5.19B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...